What is WHPM?
W.H.P.M., Inc. operates as a pivotal entity in the medical diagnostic market, specializing in the development and production of high-precision testing solutions. Their diverse portfolio encompasses Drugs of Abuse Tests, Harm Reduction Tests, Automated FIT Tests, and Fertility Diagnostic Tests. Beyond its proprietary product line, the company distinguishes itself through robust private labeling and contract manufacturing services, which empower distribution partners to maintain a competitive edge. With a focus on state-of-the-art manufacturing facilities and rigorous research protocols, WHPM remains a critical supplier for healthcare providers seeking reliable, innovative diagnostic tools. The company's upcoming participation in the ADLM 2026 trade fair serves as a testament to its ongoing commitment to industry leadership and technological advancement.
How much funding has WHPM raised?
WHPM has raised a total of $407K across 2 funding rounds:
Debt
$150K
Debt
$257K
Debt (2020): $150K with participation from PPP
Debt (2021): $257K led by PPP
Key Investors in WHPM
PPP
Public-Private Partnership
What's next for WHPM?
With the successful acquisition of late-stage capital, WHPM is well-positioned to accelerate its strategic initiatives. The focus will likely shift toward optimizing manufacturing efficiencies and expanding its footprint in the global diagnostic market. By prioritizing research and development, the company aims to introduce next-generation testing solutions that address evolving clinical needs. Furthermore, the continued investment in private labeling capabilities will likely attract new distribution partnerships, reinforcing the company's role as a foundational player in the medical diagnostics ecosystem. As the firm prepares for major industry events, the emphasis remains on scaling production capacity to meet the rising demand for accurate, accessible diagnostic testing.
See full WHPM company page
